Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Trial Profile

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Jul 2018 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.
    • 10 Jul 2018 Planned primary completion date changed from 1 Dec 2019 to 31 Dec 2019.
    • 10 Jul 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top